# Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

> **NCT03386513** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 179 (actual)

## Conditions studied

- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** IMGN632

## Key facts

- **NCT ID:** NCT03386513
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-02
- **Primary completion:** 2023-09-06
- **Final completion:** 2026-12-30
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386513, "Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03386513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*